View Author
patient cancer sarcoma treatment study group survival tissue tumor factor trial response imatinib analysis month grade phase chemotherapy tissue sarcoma disease doxorubicin therapy european oncol expression tumour cycle research bone sarcoma group result prognostic ifosfamide tissue sarcomas progression stromal tumours stromal tumors progression-free survival table article trabectedin mutation toxicity hyperthermia metastatic activity smoking eortc lymphopenia eia-alone group angiosarcoma effect progression-free journal european organization phase ii trial event level phase ii study pharmacokinetic treatment group death model prognostic factors oncology outcome non-gist breast agent status inhibitor retrospective downloaded hospital number stromal tumours eia-alone response rate retrospective analysis cyp 1a
10 Most Recent Publications
|
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
(Article)
Cesne, A. le Blay, J-Y. Grosso, F. Lardelli, P. Nieto, A. Alfaro, V. Verweij, J. Poveda, A. Casali, P.G. Demetri, G.D. Cresta, S. Maki, R.G. Balaña, C. Schöffski, P. |
2012-06-29
|
|
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study
(Article)
Issels, R.D. Lindner, L.H. Vujaskovic, Z. Wessalowski, R. Jauch, K.W. Dürr, H.R. Ploner, F. Baur-Melnyk, A. Mansmann, U. Hiddemann, W. Blay, J-Y. Judson, I.R. Verweij, J. Wust, P. Reichardt, P. Schem, B.C. Abdel-Rahman, S. Daugaard, S. Salat, C. Wendtner, C.M. |
2010-06-01
|
|
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
(Article)
Schöffski, P. Blay, J-Y. Munzert, G. Fritsch, H. Hanft, G. Aerts, C. Rapion, J. Allgeier, A. Bogaerts, J. Lacombe, D. Greve, J. de Brain, E. Machiels, J. Soria, J.C. Sleijfer, S. Wolter, P. Ray-Coquard, I. Fontaine, C. |
2010-05-14
|
|
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
(Article)
Sleijfer, S. Ouali, M. Glabbeke, M.M.B. van Krarup-Hansen, A. Rodenhuis, S. Cesne, A. le Hogendoorn, P.C.W. Verweij, J. Blay, J-Y. |
2010-01-01
|
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
(Article)
Ray-Coquard, I. Cropet, C. Guastalla, J.P. Bachelot, T. Perol, D. Chabaud, S. Hogendoorn, P.C.W. Cassier, P. Dufresne, A. Blay, J-Y. Glabbeke, M.M.B. van Sebban, C. Cesne, A. le Judson, I.R. Tredan, O. Verweij, J. Biron, P. Labidi, I. |
2009-07-01
|
|
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors
(Article)
Romeo, S. Debiec-Rychter, M. Sciot, R. Blay, J-Y. Hogendoorn, P.C.W. Glabbeke, M.M.B. van Paassen, H. van Comite, P. Eijk, R. van Oosting, J. Verweij, J. Terrier, P. Schneider, U. |
2009-06-15
|
|
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
(Article)
Erp, N.P. van Gelderblom, H. Glabbeke, M.M.B. van Oosterom, A. van Verweij, J. Guchelaar, H.J. Debiec-Rychter, M. Peng, B. Blay, J-Y. Judson, I.R. |
2008-12-15
|
|
Angiogenesis inhibition in non-GIST soft tissue sarcomas
(Article)
Sleijfer, S. Graaf, W.T.A. van der Blay, J-Y. |
2008-11-01
|
|
Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group
(Article)
Schlemmer, M. Reichardt, P. Verweij, J. Hartmann, J.T. Judson, I.R. Thyss, A. Hoogendoorn, P.C.W. Marreaud, S. Glabbeke, M.M.B. van Blay, J-Y. |
2008-11-01
|
|
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
(Article)
Sciot, R. Debiec-Rychter, M. Daugaard, S. Fisher, C. Collin, F. Glabbeke, M.M.B. van Verweij, J. Blay, J-Y. Hoogendoorn, P.C.W. |
2008-09-01
|
